Drug slows Alzheimer's but can it make a real difference? Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work. Free migraine master classes offered to healthcare professionals Classes featuring experts on migraine science will be available around the world. Ubrogepant will be the first oral CGRP antagonist for acute migraine in Canada Health Canada approves Ubrelvy (ubrogepant) for treating acute migraine, with or without aura, in adults TNFα-inhibitor biologics for rheumatic disease linked to the development of MS Study examines risk of multiple sclerosis among users of antitumour necrosis factor alpha biologics in four Canadian provinces SickKids study uncovers 134 genes linked to autism The study, which was published in Cell, is the largest whole genome sequencing study for autism in the world. Will angiotensin receptor II blockers play a role in epilepsy prevention? Study examines whether ARB therapy is associated with a decreased incidence of new onset epilepsy in patients with hypertension. Can we do anything about restless leg syndrome? When symptoms are mild, even a few lifestyle changes may provide relief, notes Dr. Noorali Bharwani. Normal tension glaucoma linked to increased risk for Alzheimer’s disease Large Taiwan study shows those with glaucoma 52% more likely to develop Alzheimer's Concussion is more than sports injuries: Who’s at risk and how Canadian researchers are seeking better diagnostics and treatments Each year, about 1% of Canadians sustain concussions, amounting to some 400,000 concussions in Canada alone. Which treatment is most effective for diabetic peripheral neuropathy? Study examines the efficacy of three monotherapies and three combination therapies for diabetic peripheral neuropathy. First Previous 24 25 26 27 28 Next Last
